02/01/2024 Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
The Ministry of Health’s Drug Advisory Committee has recommended:
- Abrocitinib 50 mg, 100 mg a...
02/01/2024 Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
The Ministry of Health’s Drug Advisory Committee has recommended:
- Abrocitinib 50 mg, 100 mg and 200 mg film-coated tablets for treating moderate-to-severe atopic dermatitis in patients who have had an inadequate response, intolerance or contraindication to at least one systemic therapy such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil.
Funding status
RAbrocitinib 50 mg, 100 mg and 200 mg film-coated tablets are recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indication from 1 March 2024.
RAbrocitinib should be used in line with additional clinical criteria for initial and continuing prescriptions for patients with moderate-to-severe atopic dermatitis.
NRMAF assistance does not apply to any formulations or strengths of baricitinib, upadacitinib or dupilumab for treating atopic dermatitis.
01/07/2022 Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
The Ministry of Health’s Drug Advisory Committee has recommended:
- Baricitinib 2 mg and 4 mg t...
01/07/2022 Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
The Ministry of Health’s Drug Advisory Committee has recommended:
- Baricitinib 2 mg and 4 mg tablets for treating adults with moderately to severely active rheumatoid arthritis;
- Tofacitinib 5 mg tablet for treating adults with moderately to severely active rheumatoid arthritis; and
- Rituximab biosimilar (Truxima) 500 mg concentrate for infusion for treating adults with severely active rheumatoid arthritis
in line with their registered indications.
Subsidy status
RBaricitinib 2 mg and 4 mg tablets and tofacitinib 5 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
RBaricitinib and tofacitinib should be used in line with the clinical criteria in the MAF checklist for initial and continuing prescriptions for patients with rheumatoid arthritis.
RRituximab biosimilar (Truxima) 500 mg concentrate for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.
NRSDL subsidy and MAF assistance does not apply to any formulations or strengths of tocilizumab, rituximab reference biologic (MabThera) or other rituximab biosimilars (such as Rixathon).